MFIMFI
BMRN icon

Mesirow Financial Investment Management - Fixed Income’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,875
Closed -$1.65M – 25
2022
Q2 		$1.65M Buy
+19,875
New +$1.58M 0.21% 108

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's BMRN Position: Q3 2022 in Review

Mesirow Financial Investment Management - Fixed Income sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 19,875 shares — an estimated $1.65M sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in BMRN in Q2 2022 and held it in 1 quarter. The position peaked at $1.65M in Q2 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 19,875 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.65M.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Mesirow Financial Investment Management - Fixed Income's BioMarin Pharmaceuticals position peaked at $1.65M in Q2 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q3 2022, filed 8 Nov 2022.